CRISPR/Cas9 Technology in Translational Biomedicine.


Journal

Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
ISSN: 1421-9778
Titre abrégé: Cell Physiol Biochem
Pays: Germany
ID NLM: 9113221

Informations de publication

Date de publication:
17 Apr 2020
Historique:
accepted: 16 03 2020
entrez: 17 4 2020
pubmed: 17 4 2020
medline: 12 11 2020
Statut: ppublish

Résumé

The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) - RNA-guided Cas9 endonuclease system has provided a fast and efficient method for precise genome editing in diverse mammalian species, including humans. The CRISPR/Cas9 technology allows generation of modifications into site-specific locations of the selected genes in one major step by carrying deletions, insertions or DNA donor-directed precise sequence modifications. Cas9 forms a nucleoprotein complex with a sequence-specific guide RNA to create double-stranded breaks in complementary DNA target. Further, double-stranded break repair machinery leads to the intended gene modifications. The CRISPR/Cas9 system is widely used technique for genome modification, editing and other biotechnology applications, such as functional annotation, a system for visualization of specific genomic loci and transcriptional control of genes. CRISPR/Cas9-mediated manipulation of the laboratory animal genomes has contributed to the understanding of gene functions and has become a popular approach for modeling human disorders. Furthermore, the growing application of CRISPR-Cas9 system to human genes emerges as an extremely powerful technology for the molecular characterization and treatment of human disease. In this review we present the essential principles of CRISPR/Cas9 technology and the recent advances in its use in translational biomedicine.

Identifiants

pubmed: 32298553
doi: 10.33594/000000224
doi:

Substances chimiques

RNA, Guide 0
Caspase 9 EC 3.4.22.-

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

354-370

Subventions

Organisme : Russian Science Foundation
ID : N 19-75-30008
Pays : Russia

Informations de copyright

© Copyright by the Author(s). Published by Cell Physiol Biochem Press.

Déclaration de conflit d'intérêts

The authors have no conflicts of interest to declare.

Auteurs

Elena I Leonova (EI)

Institute of Translational Biomedicine St. Petersburg State University, Saint Petersburg, Russia.
University of Science and Technology, Sochi, Russia, 1102.elena@gmail.com.

Raul R Gainetdinov (RR)

Institute of Translational Biomedicine St. Petersburg State University, Saint Petersburg, Russia.
St. Petersburg State University Hospital, St. Petersburg State University, Saint Petersburg, Russia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH